Novartis

Novartis shares plunge after latest clinical-trial setback

Novartis shares fell sharply after a clinical trial for a muscle-disorder treatment failed, prompting analysts to question confidence in the company’s recently acquired drug pipeline. The setback illustrates the financial and scientific risks behind major pharmaceutical acquisitions.